Financial Performance - The company's revenue for Q1 2023 was ¥78,085,173.39, representing a 7.13% increase compared to ¥72,887,112.31 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥2,417,228.83, a decrease of 127.12% from a profit of ¥8,912,462.89 in the previous year[5]. - The company's basic earnings per share were -¥0.03, down 127.27% from ¥0.11 in the same period last year[5]. - Operating profit turned negative at -¥2,364,058.33, compared to a profit of ¥9,381,414.07 in the previous period[21]. - Net profit for the current period was -¥2,520,711.19, a significant decline from ¥8,524,544.62 in the previous period[21]. - The company achieved a total comprehensive income of ¥5,380,673.81, down from ¥8,524,544.62 in the previous period[22]. Cash Flow - The cash flow from operating activities improved significantly to ¥17,673,168.97, compared to a negative cash flow of ¥15,632,963.13 in the same period last year, marking a 213.05% increase[5]. - The company reported a net cash flow from operating activities of ¥17,673,168.97, recovering from a negative cash flow of -¥15,632,963.13 in the previous period[25]. - Cash and cash equivalents increased to CNY 500,489,923.64 from CNY 425,764,874.23, representing a growth of approximately 17.5%[16]. - Cash and cash equivalents at the end of the period increased to ¥500,489,923.64, compared to ¥433,237,666.85 at the end of the previous period[26]. - The company generated cash inflows from investment activities totaling ¥166,574,437.19, with net cash flow from investment activities of ¥9,231,859.19[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥932,156,719.79, reflecting a 3.70% increase from ¥898,868,684.29 at the end of the previous year[5]. - The company's current assets reached CNY 675,995,466.59, up from CNY 647,426,048.56, indicating an increase of about 4.0%[17]. - The total liabilities of the company as of March 31, 2023, were CNY 173,361,491.14, compared to CNY 145,454,129.45 at the beginning of the year, showing an increase of around 19.2%[18]. - The company's equity attributable to shareholders reached CNY 757,009,963.12, up from CNY 751,525,806.95, reflecting a growth of about 0.5%[18]. - Total non-current assets amounted to CNY 256,161,253.20, slightly up from CNY 251,442,635.73, reflecting an increase of about 1.4%[17]. Expenses - Research and development expenses increased by 46.72% to ¥6,839,149.50, up from ¥4,661,255.97 in the previous year, indicating a focus on innovation[10]. - Total operating costs increased to ¥81,960,671.26, up from ¥73,053,209.52, reflecting a rise of 12.1%[20]. - The company reported a significant increase in operating costs, which rose by 185.80% to ¥27,537,913.38, compared to ¥9,635,450.17 in the previous year[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,963[12]. - The first quarter report of Xizang Duorui Pharmaceutical Co., Ltd. is unaudited[27].
多瑞医药(301075) - 2023 Q1 - 季度财报